Year in review 2011: Critical Care - infection

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Afshari, Arash ^a,b   Pagani, Leonardo ^a   Harbarth, Stephan ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; CARBOXYPENICILLIN PLUS UREIDO; CEFEPIME; CEFPIROME; CEFTAZIDIME; COLISTIN; ECHINOCANDIN; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN; PROCALCITONIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CANDIDEMIA; CLINICAL DECISION MAKING; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DRUG CLEARANCE; DRUG HALF LIFE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DIAGNOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SYSTEMIC MYCOSIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84871397487     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11421     Document Type: Review

References (47)

1. Charani E, Edwards R, Sevdalis N, Alexandrou B, Sibley E, Mullett D, Franklin BD, Holmes A. Behavior change strategies to influence antimicrobial prescribing in acute care: a systematic review. Clin Infect Dis 2011, 53:651-662. 10.1093/cid/cir445, 21890770.
2. Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help?. Lancet Infect Dis 2001, 1:251-261. 10.1016/S1473-3099(01)00120-7, 11871512.
3. Hulscher ME, Grol RP, van der Meer JW. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis 2010, 10:167-175. 10.1016/S1473-3099(10)70027-X, 20185095.
4. Cortoos PJ, DeWitte K, Peetermans WE, Simoens S, Laekeman G. Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother 2008, 62:189-195. 10.1093/jac/dkn143, 18397925.
5. Edwards R, Charani E, Sevdalis N, Alexandrou B, Sibley E, Mullett D, Loveday HP, Drumright LN, Holmes A. Optimisation of infection prevention and control in acute health care by use of behaviour change: a systematic review. Lancet Infect Dis 2012, 12:318-329. 10.1016/S1473-3099(11)70283-3, 22342325.
6. Coelho LM, Salluh JI, Soares M, Bozza F, Verdeal JC, Castro-Faria-Neto HC, Lapa E, Silva JR, Bozza PT, Povoa P. Patterns of C-reactive protein ratio response in severe community-acquired pneumonia: a cohort study. Crit Care 2012, 16:R53. 10.1186/cc11291, 22449513.
7. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen A, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, . Procalcitonin and Survival Study (PASS) Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328, Procalcitonin and Survival Study (PASS) Group.
8. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331. 10.1001/archinternmed.2011.318, 21824946.
9. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011, 53:379-387. 10.1093/cid/cir408, 21810753.
10. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011, 39:1792-1799. 10.1097/CCM.0b013e31821201a5, 21358400.
11. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns 2011, 37:549-558. 10.1016/j.burns.2010.04.013, 20537467.
12. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012, 38:940-949. 10.1007/s00134-012-2563-7, 22538461.
13. Afshari A, Schrenzel J, Ieven M, Harbarth S. Rapid molecular diagnostics for bloodstream infection: a new frontier?. Crit Care 2012, 16:222. 10.1186/cc11202, 22647543.
14. Frye AM, Baker CA, Rustvold DL, Heath KA, Hunt J, Leggett JE, Oethinger M. Clinical impact of a real-time PCR assay for rapid identification of staphylococcal bacteremia. J Clin Microbiol 2012, 50:127-133. 10.1128/JCM.06169-11, 3256728, 22075595.
15. Cattoir V, Merabet L, Djibo N, Rioux C, Legrand P, Girou E, Lesprit P. Clinical impact of a real-time PCR assay for rapid identification of Staphylococcus aureus and determination of methicillin resistance from positive blood cultures. Clin Microbiol Infect 2011, 17:425-431. 10.1111/j.1469-0691.2010.03233.x, 20384710.
16. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010, 51:1074-1080. 10.1086/656623, 20879856.
17. Nguyen DT, Yeh E, Perry S, Luo RF, Pinsky BA, Lee BP, Sisodiya D, Baron EJ, Banaei N. Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci. J Clin Microbiol 2010, 48:785-790. 10.1128/JCM.02150-09, 2832423, 20071556.
18. Pasqualini L, Mencacci A, Leli C, Montagna P, Cardaccia A, Cenci E, Montecarlo I, Pirro M, di Filippo F, Cistaro E, Schillaci G, Bistoni F, Mannarino E. Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. J Clin Microbiol 2012, 50:1285-1288. 10.1128/JCM.06793-11, 3318564, 22322348.
19. Wassenberg M, Kluytmans J, Erdkamp S, Bosboom R, Buiting A, van Elzakker E, Melchers W, Thijsen S, Troelstra A, Vandenbroucke-Grauls C, Visser C, Voss A, Wolffs P, Wulf M, van Zwet T, de Wit A, Bonten M. Costs and benefits of rapid screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study. Crit Care 2012, 16:R22. 10.1186/cc11184, 3396263, 22314204.
20. Wassenberg MW, Kluytmans JA, Box AT, Bosboom RW, Buiting AG, van Elzakker EP, Melchers WJ, van Rijen MM, Thijsen SF, Troelstra A, Vandenbroucke-Grauls CM, Visser CE, Voss A, Wolffs PF, Wulf MW, van Zwet AA, de Wit GA, Bonten MJ. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect 2010, 16:1754-1761. 10.1111/j.1469-0691.2010.03210.x, 20219077.
21. Uçkay I, Sax H, Iten A, Camus V, Renzi G, Schrenzel J, Perrier A, Pittet D. Effect of screening for methicillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. Infect Control Hosp Epidemiol 2008, 29:1077-1079. 10.1086/591452, 18844467.
22. Januel JM, Harbarth S, Allard R, Voirin N, Lepape A, Allaouchiche B, Guerin C, Lehot JJ, Robert MO, Fournier G, Jacques D, Chassard D, Gueugniaud PY, Artru F, Petit P, Robert D, Mohammedi I, Girard R, Cêtre JC, Nicolle MC, Grando J, Fabry J, Vanhems P. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol 2010, 31:388-394. 10.1086/650754, 20156064.
23. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med 2011, 39:2736-2742.
24. Kaminski C, Timsit JF, Dubois Y, Zahar JR, Garrouste-Orgeas M, Vesin A, Azoulay E, Feger C, Dumenil AS, Adrie C, Cohen Y, Allaouchiche B, . OUTCOMEREA Study Group Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care 2011, 15:R112. 10.1186/cc10136, 3219393, 21481266, OUTCOMEREA Study Group.
25. Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, Hernández I, Royo G, Martin-Hidalgo A. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005, 24:377-383. 10.1007/s10096-005-1346-2, 15931452.
26. de Roux A, Ewig S, García E, Marcos MA, Mensa J, Lode H, Torres A. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006, 27:795-800. 10.1183/09031936.06.00058605, 16585087.
27. Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J, Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346. 10.1136/thx.2010.143982, 21257985.
28. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, . EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, EPIC II Group of Investigators.
29. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011, 15:R267. 10.1186/cc10545, 3388653, 22085732.
30. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care 2011, 15:R206. 10.1186/cc10441, 3334750, 21914174.
31. Pagani L, Afshari A, Harbarth S. Year in review 2010: Critical Care - infection. Crit Care 2011, 15:238. 10.1186/cc10425, 3388701, 22152031.
32. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011, 11:834-844. 10.1016/S1473-3099(11)70177-3, 21784708.
33. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709. 10.1093/cid/cis270, 22467668.
34. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53:879-884. 10.1093/cid/cir611, 21900484.
35. Bergen PJ, Li J, Nation RL. Dosing of colistin - back to basic PK/PD. Curr Opin Pharmacol 2011, 11:464-469. 10.1016/j.coph.2011.07.004, 3183124, 21835694.
36. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-680. 10.1093/cid/cir934, 22322268.
37. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629. 10.1093/cid/cir895, 22247123.
38. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011, 139:1148-1155. 10.1378/chest.10-1556, 3087458, 20864609.
39. Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care 2011, 15:R198. 10.1186/cc10366, 3387640, 21846332.
40. Muskett H, Shahin J, Eyres G, Harvey S, Rowan K, Harrison D. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care 2011, 15:R287. 10.1186/cc10574, 3388661, 22126425.
41. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294. 10.1128/AAC.01733-10, 3122440, 21555763.
42. Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, Park KH, Han SH. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother 2012, 56:3950-3956. 10.1128/AAC.06258-11, 22526315.
43. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ, . Mycoses Study Group Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122. 10.1093/cid/cis021, 22412055, Mycoses Study Group.
44. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. , http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm
45. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007, 370:1875-1877. 10.1016/S0140-6736(07)61604-3, 17959239.
46. Powers JH. Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions. Stat Med 2008, 27:343-352. 10.1002/sim.3138, 18186148.
47. Powers JH. Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials. Clin Infect Dis 2012, 54:1710-1713. 10.1093/cid/cis274, 22467671.